CV Sciences, Inc. (CVSI)
CVSI is quoted over the counter, not listed on an exchange. CV Sciences, Inc. files reports with the SEC; the numbers below come from SEC filings and from daily closes, each with its source.
Closes: Yahoo Finance daily closes, last bar 2026-11-16.
Profile
| Field | Value |
|---|---|
| Ticker | CVSI, quoted over the counter |
| SEC CIK | 0001510964 |
| OTC Markets tier | OTCQB (price source, 2026-11-13) |
| SEC industry code | Pharmaceutical Preparations |
| Business address | San Diego, CA |
| Incorporated in | DE |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | States substantial doubt about continuing as a going concern. "The Company's financial operating results and accumulated deficit, amongst other factors, raise substantial doubt about the Company's ability to continue as a going concern." | 10-Q 2026-11-13 |
| Cash and burn | $308K cash; operating cash flow -$43K a quarter. | Report 2026-09-30 |
| Shares outstanding | 242,184,128 (2026-11-05); 184,263,663 a year earlier; 154,604,789 three years earlier. | Cover page 2026-11-05 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Haskell & White LLP, Irvine, California, United States | PCAOB Form AP 2026-04-13 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $115K, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $3.0M | -$93K | $63K | $308K | $0 | $12.5M | 10-Q 2026-11-13 |
| Q2 2026 2026-06-30 | $3.0M | -$775K | $20K | $266K | $18K | $12.7M | 10-Q 2026-08-13 |
| Q1 2026 2026-03-31 | $3.2M | -$643K | $101K | $309K | $72K | $13.4M | 10-Q 2026-05-15 |
| Q4 2025 2025-12-31 | $3.3M | -$206K | -$354K | $278K | $1.6M | $13.8M | 10-K 2026-03-26 |
| Q3 2025 2025-09-30 | $3.3M | -$382K | -$259K | $381K | $1.3M | $14.4M | 10-Q 2026-11-13 |
| Q2 2025 2025-06-30 | $3.6M | -$261K | $287K | $886K | $1.5M | $15.0M | 10-Q 2026-08-13 |
| Q1 2025 2025-03-31 | $3.6M | -$109K | -$81K | $812K | $1.7M | $15.3M | 10-Q 2026-05-15 |
| Q4 2024 2024-12-31 | $3.9M | -$726K | -$164K | $454K | $677K | $15.7M | 10-K 2026-03-26 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2022-03-31 |
| Latest annual report | 10-K | 2026-03-26 |
| Latest quarterly / interim | 10-Q | 2026-11-13 |
| Latest current report | 8-K | 2026-11-12 |
| Latest proxy | DEF 14A | 2026-04-15 |
Source: SEC EDGAR submissions feed, 434 recent filings. All filings on EDGAR.
The full dossier has every filing, quarterly and annual financials, the health record and a price chart.
Open the full dossier